Table 3.

Effects of depleting donor SJL T cells on subsequent development of relapsing disease in SJL-Thy1^a recipients

Time of Antibody Treatment	Treatment	Incidence of relapsing disease after treatment	Av. max. relapsing disease grade after treatment ^* (Mean ± SEM)
During 1^st Remission	Isotype-matched Ab	16/18^#	2.8 ± 0.19
During 1^st Remission	Anti-Thy1.2	1/18^#	1.0
During 2^nd Remission	Isotype-matched Ab	9/10^{^}	2.8 ± 0.22
During 2^nd Remission	Anti-Thy1.2	1/8^{^}	1.0
During 3^rd/4^th Remissions	Isotype-matched Ab	4/5^&	3.3 ± 0.25
During 3^rd/4^th Remissions	Anti-Thy1.2	1/7^&	1.0

PLP_139–151-primed and in vitro activated donor SJL lymph node cells were transferred into SJL-Thy-1^a recipient mice. These mice developed acute EAE and then entered the remission cycle. At this time (1^st remission), groups of mice were treated with three doses of anti-Thy-1.2 or isotype-matched antibodies over the next six days. These mice were observed for subsequent development of relapsing EAE. Of the remaining untreated mice that proceeded to the first relapse and then second remission, groups of mice were similarly treated with anti-Thy-1.2 antibodies and observed for subsequently development of relapsing EAE. The remaining untreated mice went through the third and some through the 4^th remission. These mice were treated similarly. Because of the small number of mice in these groups, the mice were pooled for analysis. Disease was monitored for 60 days after antibody treatment. Data were combined from multiple experiments with varied group sizes.

only include mice showing relapsing disease after administration of antibodies.

Fisher’s Exact Tests:

two-tailed p value < 0.0001

^{^}

two-tailed p value = 0.0029

two-tailed p value = 0.072

one-tailed p value = 0.044